1. 4P FDG PET derived metabolic tumor volume (MTV) and its transcriptomic correlates as biomarker to predict efficacy of immune checkpoint inhibitors (ICB) alone or in combination with chemotherapy in advanced NSCLC: A multicentric study. (December 2022) Authors: Dall'Olio, F.G.; Garcia, C.A.; Zrafi, W.S.; Fortunati, E.; Bettayeb, A.; Zalcman, G.; Remon Masip, J.; Hendriks, L.; Tagliamento, M.; Bonardel, G.; Helissey, C.; Roelants, V.; Fourquet, A.; Aboubakar, F.; Chaput-Gras, N.; Passiglia, F.; Monnet, I.; Planchard, D.; Barlesi, F.; Besse, B. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB1170 First results of the rheumatoid arthritis handscan registry leeuwarden. (12th June 2018) Authors: Al Hasan, A.; Bos, R.; Veeger, N.; Zhang, D.; Hendriks, L.; Wink, F.; Schilder, A.; Reimann, F.; Bergsma, K. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Deep Learning Applied to the Asteroseismic Modeling of Stars with Coherent Oscillation Modes. (23rd August 2019) Authors: Hendriks, L.; Aerts, C. Journal: Publications of the Astronomical Society of the Pacific Issue: Volume 131:Number 1004(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0336 Effectiveness of Abatacept, Rituximab or A TNFI after Failure of the First Tnfi: Results of A Multi-Centered Pragmatic Rct. (10th June 2014) Authors: Manders, S.; Kievit, W.; Adang, E.; Brus, H.; Bernelot Moens, H.; Hartkamp, A.; Hendriks, L.; Vonkeman, H.; Brouwer, E.; Westhovens, R.; Visser, H.; van de Laar, M.; van Riel, P. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 509 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OC-0176 Risk factors for cognitive impairment in NSCLC: Secondary findings of the NVALT-11 study. (August 2021) Authors: Zeng, H.; Hendriks, L.; Witlox, W.; Groen, H.; Dingemans, A.; Praag, J.; Belderbos, J.; Houben, R.; van der Noort, V.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OC-0438 Proton-therapy and concurrent chemotherapy in stage III NSCLC: effects on hematological toxicity. (May 2022) Authors: Cortiula, F.; Hendriks, L.; Steens, M.; Dursun, S.; Bootsma, G.; Canters, R.; Rinaldi, I.; Taasti, V.T.; Houben, R.; Reynders, K.; Peeters, S.; Angrisani, A.; Hattu, D.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OC-0557 AI-based NSCLC detection and segmentation: faster and more prognostic than manual segmentation. (August 2021) Authors: Primakov, S.; Ibrahim, A.; van Timmeren, J.; Wu, G.; Keek, S.; Beuque, M.; Granzier, R.; Scrivener, M.; Sanduleanu, S.; Kayan, E.; Halilaj, I.; Wu, J.; Monshouwer, R.; Gietema, H.; Hendriks, L.; Morin, O.; Jochems, A.; Woodruff, H.; Lambin, P. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PD-0844 Sarcopenia evolution in stage III lung cancer treated with photon or proton chemo-radiotherapy. (August 2021) Authors: Angrisani, A.; Hattu, D.; Hendriks, L.; Peeters, S.; Reymen, B.; Van Loon, J.; Verhoeven, K.; In 't Ven, L.; Dhont, J.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S679 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PO-1025: Prognostic factors for PFS and OS in radically treated patients with oligometastatic NSCLC. (November 2020) Authors: LeenderS, M.; Robeers, R.; Hendriks, L.; Van Loon, J.; Bootsma, G.; Wanders, R.; Pitz, C.; Reymen, B.; Houben, R.; Van Baardwijk, A.; Verhoeven, K.; Peeters, S.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. PO-1053 cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. (May 2022) Authors: Witlox, W.; Ramaekers, B.; Lacas, B.; Le Pechoux, C.; Sun, A.; Wang, S.; Hu, C.; Redman, M.; van der Noort, V.; Li, N.; Guckenberger, M.; van Tinteren, H.; Hendriks, L.; Groen, H.; Joore, M.; de Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S887 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗